International Journal of Hematology

Article	Citations
COVID-19-associated coagulopathy and disseminated intravascular coagulation	289
Recent advances in the research and management of sepsis-associated DIC	55
Engineering the next generation of CAR-NK immunotherapies	51
Multiple myeloma with high-risk cytogenetics and its treatment approach	44
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine	37
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia	35
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment	32
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm	24
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination	23
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia	22
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR us	19
Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma	19
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study	19
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives	18
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities	17
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients	17
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation	17
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023	16
Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations	16
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?	16
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial	16
Genetic landscape of chronic myeloid leukemia	15
A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma	14
Anakinra for the treatment of adult secondary HLH: a retrospective experience	14
FLT3-targeted treatment for acute myeloid leukemia	14

Diversity of disseminated intravascular coagulation and selection of appropriate treatments	14
Risk factors for high-dose methotrexate-induced nephrotoxicity	14
Antibody response to COVID-19 vaccination in patients with lymphoma	13
Validation of sepsis-induced coagulopathy score in critically ill patients with septic shock: post hoc analysis of a nationwide multicenter observational study in Japan	13
Bringing mass spectrometry into the care of patients with multiple myeloma	13
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19	13
T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia	12
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation	12
Updated guidelines for chronic active Epstein–Barr virus disease	12
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study	12
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis	12
Clinical features of 35 Down syndrome patients with transient abnormal myelopoiesis at a single institution	12
Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients	12
Current status and novel strategy of CML	11
Expression of activated integrin β7 in multiple myeloma patients	11
The mutual crosstalk between iron and erythropoiesis	11
Patient’s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome	11
Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation	11
Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature	11
Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis	10
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study	10
Characteristics and transplant outcome of myeloid sarcoma: a single-institute study	10
Prevalence and molecular spectrum of α- and β-globin gene mutations in Hainan, China	10
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia	10
Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature	10
Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura	10
Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility	10
Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome	10
Effect of hypofibrinogenemia on obstetrical disseminated intravascular coagulation in Japan in 2018: a multicenter retrospective cohort study	10
Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study	10
Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study	10
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study	10
A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation	10
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study	10
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblasti	9
Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis	9
Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma	9
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody	9
High incidence of venous thrombosis in patients with moderate-to-severe COVID-19	9
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial	9
Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis	8
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marke	8
Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation	8
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis	8
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma	8
Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia	8
Treatment-free remission and immunity in chronic myeloid leukemia	8
Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual	8
Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis	8
Plasma proteomics associated with autoimmune coagulation factor deficiencies reveals the link between inflammation and autoantibody development	8

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial	8
Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes	8
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma	8
The role of specialized cell cycles during erythroid lineage development: insights from single-cell RNA sequencing	7
Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: resu	7
Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study	7
Epigenetic regulation by ASXL1 in myeloid malignancies	7
The role of epigenetics in T-cell lymphoma	7
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation	7
Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide	7
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience	7
Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A	7
Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning	7
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia	7
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria	7
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial	7
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease	7
Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review	7
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China	7
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges	7
Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review	7
Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD	7
Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease	7
Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease	7
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine	7
Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan	7
The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia	7
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis	7
Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study	6
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma	6
All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16	6
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura	6
Early central nervous system relapse of monomorphic epitheliotropic intestinal T-cell lymphoma after cord blood transplantation	6
Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease	6
Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis	6
Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan	6
Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases	6
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy	6
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies	6
Quality of life and patient-reported outcomes in chronic severe neutropenia conditions	6
The clinical application of SNP-based next-generation sequencing (SNP-NGS) for evaluation of chimerism and microchimerism after HLA-mismatched stem cell microtransplantation	6
Cardiovascular risk factors among adult patients with haemophilia	6
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study	6
Relationship between serum zinc level and sepsis-induced coagulopathy	6
Recent progress in ITP treatment	6
Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation	6
Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome	6
Novel treatments for myelofibrosis: beyond JAK inhibitors	6
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3–ITD-mutated acute myeloid leukemia	6
Phenotype-oriented anticoagulant therapy for sepsis: still a work in progress	6
Resilient T-cell responses in patients with advanced cancers	6
Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day	6
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial	6
Severe systemic inflammation mimicking TAFRO syndrome following COVID-19	6
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation	6
Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1	5
Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes	5
Comprehensive molecular understanding of pediatric acute myeloid leukemia	5
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism	5
Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis	5
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma	5
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial	5
Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological maligna	5
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China	5
Asciminib as a third line option in chronic myeloid leukemia	5
Reference intervals of red blood cell parameters and platelet count for healthy adults in Japan	5
Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy	5
Virus-infected peripheral blood plasmablasts in a patient with severe fever with thrombocytopenia syndrome	5
Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan	5
Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography	5
Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission	5
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group	5
Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma	5
Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study	5
Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan	5
Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal	5
ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor	5
Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation	5
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor	5
Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era	5

Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation	5
A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia	5
Progress of modern imaging modalities in multiple myeloma	5
CXCR4 expression by mesenchymal stromal cells is lost after use of enzymatic dissociation agents, but preserved by use of non-enzymatic methods	5
Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome	5
VEXAS syndrome	5
Latest trends in the incidence of Helicobacter pylori-uninfected gastric mucosa-associated lymphoid tissue lymphoma at the Cancer Institute Hospital, Japan	5
Optimization of lymphapheresis for manufacturing autologous CAR-T cells	5
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pi	5
ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database	5
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience	5
Evolution and optimization of therapies for acute lymphoblastic leukemia in infants	4
Novel immunotherapies in multiple myeloma	4
Extracellular vesicle-mediated immunoregulation in cancer	4
FLT3 targeting in the modern era: from clonal selection to combination therapies	4
Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group	4
Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults	4
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation	4
Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation	4
Clinical, laboratory, and mutational profile of children with glucose phosphate isomerase deficiency: a single centre report	4
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation	4
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma	4
Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation	4
Bosutinib-induced lung injury: a report of two cases and literature review	4
Histidine decarboxylase deficiency inhibits NBP-induced extramedullary hematopoiesis by modifying bone marrow and spleen microenvironments	4
Isolated thrombosis after COVID-19 vaccination: case series	4
Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal	4
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan	4
Improving allogeneic stem cell transplantation in myelofibrosis	4
Heme as a differentiation-regulatory transcriptional cofactor	4
Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib	4
A novel germline GATA2 frameshift mutation with a premature stop codon in a family with congenital sensory hearing loss and myelodysplastic syndrome	4
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy	4
Familial hemophagocytic lymphohistiocytosis syndrome due to lysinuric protein intolerance: a patient with a novel compound heterozygous pathogenic variant in SLC7A7	4
Increasing numbers of CD19 + CD24highCD38high regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune	4
The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell	4
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia	4
Novel technologies for improving the safety and efficacy of CAR-T cell therapy	4
Acquired hypofibrinogenemia in a patient with multiple myeloma	4
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome	4
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia	4
The pathogenesis of cancer-associated thrombosis	4
Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphom	4
Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis	4
Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute	4
Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases	4
RNA modifications in hematological malignancies	4
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy	4
Induction of enucleation in primary and immortalized erythroid cells	4
A meta-analysis of risk factors associated with platelet transfusion refractoriness	4
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency	4
Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies	4
Prevention of acute graft-versus-host disease in adult T-cell leukemia–lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation	4
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient	4
Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance	4
Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation	4
Risk factors for unplanned removal of central venous catheters in hospitalized children with hematological and oncological disorders	4
Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T	4
Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome	4
MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia	4